Company intelligence / Profile preview
Seres Therapeutics
Cambridge, Massachusetts, USAserestherapeutics.com ↗
- Ownership
- Public · MCRB
- Development stage
- Commercial
01
Overview
Seres Therapeutics pioneered the development and FDA approval of VOWST™, the first-ever oral live biotherapeutic, which was sold to Nestlé Health Science in September 2024[2].
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Live biotherapeuticsbacterial consortia
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Nestlé Health Science (VOWST™ was sold to them in September 2024)[2]
04
Financials
- Market cap
- $20.8M
- Total revenue
- $789K
- Enterprise value
- $39M
Beyond the preview
Go deeper on Seres Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seres Therapeutics.